ID

35803

Descripción

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus; ODM derived from: https://clinicaltrials.gov/show/NCT02420262

Link

https://clinicaltrials.gov/show/NCT02420262

Palabras clave

Versiones (1)
  1. 24/3/19 24/3/19 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

24 de marzo de 2019

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Diabetes NCT02420262

Inglés

Eligibility Diabetes NCT02420262

1 formularios  
  1. StudyEvent: Eligibility
    1. Eligibility Diabetes NCT02420262
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
male or female, age at least 18 years at the time of signing informed consent
Descripción

Age | Informed Consent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2]
C0021430
type 2 diabetes subjects (diagnosed clinically) at least 6 months prior to screening
Descripción

Diabetes Mellitus, Non-Insulin-Dependent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0011860
hba1c (glycosylated haemoglobin) 7.0-10.0% [53mmol/mol-86mmol/mol] (both inclusive) by central laboratory analysis
Descripción

Hemoglobin A1c measurement

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0474680
current treatment with iglar (insulin glargine) for at least 90 calendar days prior to screening
Descripción

Insulin Glargine

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0907402
stable daily dose of iglar between 20 units and 50 units (both inclusive) for at least 56 calendar days prior to screening. individual fluctuations of plus/minus 10% within the 56 calendar days prior to screening are acceptable, however on the day of screening total daily dose should be within the range of 20 units-50 units both inclusive
Descripción

Insulin Glargine Daily Dose Stable

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0907402
UMLS CUI [1,2]
C2348070
UMLS CUI [1,3]
C0205360
stable daily dose of metformin (at least 1500 mg or max tolerated dose) for at least 90 calendar days prior to screening
Descripción

Metformin Daily Dose Stable

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0025598
UMLS CUI [1,2]
C2348070
UMLS CUI [1,3]
C0205360
body mass index (bmi) below or equal to 40 kg/m^2
Descripción

Body mass index

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1305855
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria in a period of 90 calendar days before screening
Descripción

Antidiabetics | Anti-Obesity Agents | Exception Inclusion criteria

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0935929
UMLS CUI [2]
C0376607
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C1512693
anticipated initiation or change in concomitant medications in excess of 14 calendar days known to affect weight or glucose metabolism, such as weight loss/modifying (e.g.; sibutramine, orlistat, thyroid hormones, corticosteroids)
Descripción

Pharmaceutical Preparations Affecting Body Weight | Pharmaceutical Preparations Affecting Glucose metabolism | Weight-Loss Agents | sibutramine | orlistat | Thyroid Hormones | Adrenal Cortex Hormones

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0392760
UMLS CUI [1,3]
C0005910
UMLS CUI [2,1]
C0013227
UMLS CUI [2,2]
C0392760
UMLS CUI [2,3]
C0596620
UMLS CUI [3]
C0376606
UMLS CUI [4]
C0074493
UMLS CUI [5]
C0076275
UMLS CUI [6]
C0040135
UMLS CUI [7]
C0001617
impaired liver function, defined as alanine aminotransferase (alt) at least 2.5 times upper limit of normal
Descripción

Liver Dysfunction | Alanine aminotransferase increased

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0086565
UMLS CUI [2]
C0151905
renal impairment egfr (electronic case report form) below 60 ml/min/1.73 m^2 as per ckd-epi (chronic kidney disease epidemiology collaboration)
Descripción

Renal Insufficiency | Estimated Glomerular Filtration Rate

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1565489
UMLS CUI [2]
C3811844
screening calcitonin at least 50 ng/l
Descripción

Calcitonin measurement

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0201924
history of pancreatitis (acute or chronic)
Descripción

Pancreatitis | Pancreatitis, Chronic

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0030305
UMLS CUI [2]
C0149521
personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2
Descripción

Medullary carcinoma of thyroid | Familial medullary thyroid carcinoma | Multiple Endocrine Neoplasia Type

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0238462
UMLS CUI [2]
C1833921
UMLS CUI [3,1]
C0027662
UMLS CUI [3,2]
C0332307
Volver a la parte superior de la página

Similar models

Eligibility Diabetes NCT02420262

1 formularios
  1. StudyEvent: Eligibility
    1. Eligibility Diabetes NCT02420262
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Age | Informed Consent
Item
male or female, age at least 18 years at the time of signing informed consent
boolean
C0001779 (UMLS CUI [1])
C0021430 (UMLS CUI [2])
Diabetes Mellitus, Non-Insulin-Dependent
Item
type 2 diabetes subjects (diagnosed clinically) at least 6 months prior to screening
boolean
C0011860 (UMLS CUI [1])
Hemoglobin A1c measurement
Item
hba1c (glycosylated haemoglobin) 7.0-10.0% [53mmol/mol-86mmol/mol] (both inclusive) by central laboratory analysis
boolean
C0474680 (UMLS CUI [1])
Insulin Glargine
Item
current treatment with iglar (insulin glargine) for at least 90 calendar days prior to screening
boolean
C0907402 (UMLS CUI [1])
Insulin Glargine Daily Dose Stable
Item
stable daily dose of iglar between 20 units and 50 units (both inclusive) for at least 56 calendar days prior to screening. individual fluctuations of plus/minus 10% within the 56 calendar days prior to screening are acceptable, however on the day of screening total daily dose should be within the range of 20 units-50 units both inclusive
boolean
C0907402 (UMLS CUI [1,1])
C2348070 (UMLS CUI [1,2])
C0205360 (UMLS CUI [1,3])
Metformin Daily Dose Stable
Item
stable daily dose of metformin (at least 1500 mg or max tolerated dose) for at least 90 calendar days prior to screening
boolean
C0025598 (UMLS CUI [1,1])
C2348070 (UMLS CUI [1,2])
C0205360 (UMLS CUI [1,3])
Body mass index
Item
body mass index (bmi) below or equal to 40 kg/m^2
boolean
C1305855 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Antidiabetics | Anti-Obesity Agents | Exception Inclusion criteria
Item
treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria in a period of 90 calendar days before screening
boolean
C0935929 (UMLS CUI [1])
C0376607 (UMLS CUI [2])
C1705847 (UMLS CUI [3,1])
C1512693 (UMLS CUI [3,2])
Pharmaceutical Preparations Affecting Body Weight | Pharmaceutical Preparations Affecting Glucose metabolism | Weight-Loss Agents | sibutramine | orlistat | Thyroid Hormones | Adrenal Cortex Hormones
Item
anticipated initiation or change in concomitant medications in excess of 14 calendar days known to affect weight or glucose metabolism, such as weight loss/modifying (e.g.; sibutramine, orlistat, thyroid hormones, corticosteroids)
boolean
C0013227 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0005910 (UMLS CUI [1,3])
C0013227 (UMLS CUI [2,1])
C0392760 (UMLS CUI [2,2])
C0596620 (UMLS CUI [2,3])
C0376606 (UMLS CUI [3])
C0074493 (UMLS CUI [4])
C0076275 (UMLS CUI [5])
C0040135 (UMLS CUI [6])
C0001617 (UMLS CUI [7])
Liver Dysfunction | Alanine aminotransferase increased
Item
impaired liver function, defined as alanine aminotransferase (alt) at least 2.5 times upper limit of normal
boolean
C0086565 (UMLS CUI [1])
C0151905 (UMLS CUI [2])
Renal Insufficiency | Estimated Glomerular Filtration Rate
Item
renal impairment egfr (electronic case report form) below 60 ml/min/1.73 m^2 as per ckd-epi (chronic kidney disease epidemiology collaboration)
boolean
C1565489 (UMLS CUI [1])
C3811844 (UMLS CUI [2])
Calcitonin measurement
Item
screening calcitonin at least 50 ng/l
boolean
C0201924 (UMLS CUI [1])
Pancreatitis | Pancreatitis, Chronic
Item
history of pancreatitis (acute or chronic)
boolean
C0030305 (UMLS CUI [1])
C0149521 (UMLS CUI [2])
Medullary carcinoma of thyroid | Familial medullary thyroid carcinoma | Multiple Endocrine Neoplasia Type
Item
personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2
boolean
C0238462 (UMLS CUI [1])
C1833921 (UMLS CUI [2])
C0027662 (UMLS CUI [3,1])
C0332307 (UMLS CUI [3,2])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial